The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
AnGes to Invest US$2 Million in Canada’s Vasomune
Osaka University spinoff AnGes said on December 26 that it will invest in Canadian biopharmaceutical firm Vasomune Therapeutics. The investment worth US$2 million is to take place in January next year. AnGes and Vasomune inked a joint development deal in…
To read the full story
Related Article
- New Study of Vasomune-Partnered AV-001 Cleared in Canada: AnGes
September 5, 2025
- AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
BUSINESS
- Pharma Leaders Press for Drug Pricing Overhaul at New Year’s Confab
January 8, 2026
- Generic Entry into DPP-4 Class Poised to Accelerate in 2026
January 7, 2026
- Takeda Files Polycythemia Vera Drug Rusfertide in US
January 7, 2026
- Daito Snags China Approval for Iguratimod, Its Third Product
January 7, 2026
- China Accepts BLA for Leqembi Subcutaneous Autoinjector: Eisai
January 7, 2026
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…